In addition, the researchers have developed a novel whole tumor cell vaccine platform, which successfully solves the two core bottlenecks of traditional whole tumor cell vaccines through intracellular gelation technology combined with cell surface engineering of CD47 blockade and damage-related molecular pattern exposure 69. This evidence concerns the gene CD47 and neoplasm.